Friday Pipeline Update: Three deals file as pipeline begins to awaken

Company:  Contineum Therapeutics, Inc.

Symbol: CTNM (Nasdaq)

Description:  They are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need.

Shares: TBD

Price Range: TBD

Trade Date:  TBD

Underwriter(s): Goldman Sachs, Morgan Stanley, Stifel, RBC Capital

Link to Prospectus: Filed: 3-15-24

Company:  Centuri Holdings, Inc.

Symbol: CTRI (NYSE)

Description:  Centuri is a leading, pure-play North American utility infrastructure services company with over 110 years of operating history that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses.

Shares: TBD

Price Range: TBD

Trade Date:  TBD

Underwriter(s): UBS Investment Bank, BofA Securities, J.P. Morgan, Wells Fargo Securities

Co-Manager(s): Baird, KeyBanc Capital, Siebert Williams Shank

Link to Prospectus: Filed: 3-22-24

Company:  Ibotta, Inc.

Symbol: IBTA (NYSE)

Description:  Ibotta’s mission is to Make Every Purchase Rewarding. Their technology allows CPG brands to deliver digital promotions to over 200 million consumers through a single, convenient network called the Ibotta Performance Network (IPN).

Shares: TBD

Price Range: TBD

Trade Date:  TBD

Underwriter(s): Goldman Sachs, Citigroup, BofA Securities, Evercore ISI, UBS Investment Bank, Wells Fargo Securities

Co-Manager(s): Citizens JMP, Needham & Co., Raymond James

Link to Prospectus: Filed: 3-22-24

Company:  Boundless Bio, Inc.

Symbol: BOLD (Nasdaq)

Description:  They are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients.

Shares: 6.25 million

Price Range: $15.00-$17.00

Market Cap: $334m-$378m

Trade Date:  Thursday, 3/28

Underwriter(s): Goldman Sachs, Leerink Partners, Piper Sandler, Guggenheim Securities

Link to Prospectus: Terms Added: 3-21-24